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Considerable therapeutic advances for the treatment of vasculitis of the young have been made in the past
10 years, including the development of outcome measures that facilitate clinical trial design. Notably, these include:
a recognition that some patients with Kawasaki Disease require corticosteroids as primary treatment combined with
IVIG; implementation of rare disease trial design for polyarteritis nodosa to deliver the first randomised controlled
trial for children; first clinical trials involving children for anti-neutrophil cytoplasmic antibody (ANCA) vasculitis; and
identification of monogenic forms of vasculitis that provide an understanding of pathogenesis, thus facilitating
more targeted treatment. Robust randomised controlled trials for Henoch Schönlein Purpura nephritis and Takayasu
arteritis are needed; there is also an over-arching need for trials examining new agents that facilitate corticosteroid
sparing, of particular importance in the paediatric population since glucocorticoid toxicity is a major concern.Background
Primary systemic vasculitides of the young are relatively
rare diseases, but are associated with significant morbid-
ity and mortality, particularly if there is diagnostic delay
[1, 2]. There have been a number of notable advances re-
cently in the field of paediatric vasculitis research, in-
cluding the development of classification criteria; and
tools to assess disease outcome for use in clinical trials
and other research involving children with vasculitis [3,
4]. Treatment regimens continue to improve, with the
use of different immunosuppressive medications and
newer therapeutic approaches such as biologic agents
[5–7]. With the exception of Kawasaki Disease, most of
current treatment approaches for paediatric vasculitides
are based on evidence from small case series, anecdotal
observations, or adult studies [5–7]. Therefore, treat-
ment differs substantially throughout Europe; and even
within a single country, experience and practices vary
considerably. Given that vasculitides are rare, conducting
large randomised controlled trials using traditional clin-
ical trial design is usually not feasible. There is, however,
a need for a standardized approach to the management
of these rare paediatric rheumatic diseases [8]. The* Correspondence: d.eleftheriou@ucl.ac.uk
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in Europe [8]) project has been set up to address this
unmet need, and one of the main aims is to provide rec-
ommendations for the management of paediatric rheum-
atological diseases in European countries. Within this
context the SHARE vasculitis working group have re-
cently provided consensus and (where possible) evi-
dence-based statements to optimize and harmonize
management of vasculitis (manuscript in preparation). A
detailed description of this as yet unpublished guidance
is beyond the scope of this review. It is also currently
unclear how the impact of the SHARE guidance will be
assessed for all the vasculitides; comparative effective-
ness research methodologies may be required within the
context of national or international patient registries. In-
deed this approach is already underway for Kawasaki
disease (KD), in the context of a British Paediatric Sur-
veillance Unit study specifically examining the impact of
new clinical guidelines for KD in the UK.
This review summarises therapeutic advances in
current management strategies for systemic vasculitides,
and describes important unmet needs. At the time of
writing this review, the SHARE guidelines are not yet
published; however, we have aligned the descriptions of
vasculitis treatment with the SHARE recommendations,
which the reader should refer to (when these become
available) for more detailed guidance.This article is distributed under the terms of the Creative Commons Attribution
ons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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IgA vasculitis is the new term for Henoch-Schönlein
purpura (HSP), and is the commonest systemic vasculitis
in childhood [9]. For the purposes of this review, how-
ever, we will use the term HSP since that is the term
used in the paediatric classification criteria [4], and the
one most paediatricians are familiar with. It is defined in
the latest Chapel Hill nomenclature (2012) as: vasculitis
with IgA1-dominant immune deposits affecting small
vessels (predominantly capillaries, venules, or arterioles);
often involving skin, gastrointestinal tract and frequently
causes arthritis; and associated with glomerulonephritis
which is indistinguishable from IgA nephropathy [10].
Classification criteria (Ankara 2008) are: palpable pur-
pura in a predominantly lower limb distribution with at
least 1 of 4 of: diffuse abdominal pain; any biopsy show-
ing IgA deposition (mandatory criterion if rash is atyp-
ical); arthritis and/or arthralgia; haematuria and/or
proteinuria [4]. HSP has a variable and often relapsing
course without specific laboratory findings, with a third
of children having symptoms up to two weeks; another
third up to 1 month; and recurrence of symptoms within
4 months of resolution in the remaining third [11].
Henoch–Schönlein nephritis (HSN) accounts for 1.6–
3 % of all childhood cases of end-stage renal failure
(ESRF) in the UK [12]. Generally speaking, HSP is a
more severe illness in adults than in children [13].
Therapeutic advances
There is a very poor evidence base to guide the manage-
ment of HSP, particularly for those with the severe forms
of HSP nephritis (HSPN), and thus very few true thera-
peutic advances. Early morbidity in the disease is due to
GI involvement; late morbidity and the most important
overall determinant of poor outcome is renal involvement
[11]. In children the management of HSP is mainly con-
servative because the extra renal manifestations are usu-
ally self-limited [14]. Arthritis responds well to non-
steroidal anti-inflammatory drugs (NSAIDs) [14]. Severe
skin lesions and gastrointestinal involvement could require
a short course of an oral corticosteroid [14]. Controlled
studies have shown that corticosteroids do not prevent
renal disease [15, 16]. Despite that, patients with severe
renal involvement usually do require corticosteroids com-
bined with other immunosuppressive agents, and some-
times anti-proteinuric and antihypertensive agents [13].
Summary of the SHARE guidelines for HSP
The SHARE initiative represents an important major
therapeutic contribution since it provides consensus
guidance for the management of HSP and HSPN,
amongst other vasculitides [8]. In anticipation that these
will be published imminently, a brief overview of the
SHARE management algorithm for HSPN is as follows.Children with microscopic haematuria without renal
dysfunction or proteinuria, and those with non-persist-
ent mild-moderate proteinuria usually do not require
any specific therapeutic intervention other than a
“watchful waiting approach” since the prognosis is excel-
lent. Those with more severe proteinuria and/or impaired
glomerular filtration, and those with persistent proteinuria
should be reviewed by a paediatric nephrologist, and a
renal biopsy is usually recommended. Treatment there-
after includes first line therapy with corticosteroids: oral
for all; and initially intravenous pulsed methylpredniso-
lone for those with more severe renal involvement. For
the severest cases, intravenous cyclophosphamide is usu-
ally required (sometimes with plasma exchange: seek ex-
pert advice) as additional first line treatment combined
with corticosteroids. Immunosuppressants including aza-
thioprine, mycophenolate mofetil (MMF), or intravenous
cyclophosphamide may be considered as second-line
agents for those with moderate HSPN. Whilst awaiting
publication of the SHARE guidelines, for a comprehensive
review of the treatment of HSPN, the reader is referred to
[17]. It must be emphasised, however, that in the absence
of robust data for evidence supporting the treatment of
nephritis, even in view of the much anticipated SHARE
guidance, a randomised controlled trial for the treatment
of HSPN is urgently needed.
ANCA associated vasculitis (AAV)
Antineutrophil cytoplasmic autoantibody (ANCA)-asso-
ciated vasculitides (AAV) comprise granulomatosis with
polyangiitis (GPA; previously referred to as Wegener’s
granulomatosis), microscopic polyangiitis (MPA), eo-
sinophilic granulomatous polyangiitis (EGPA; previously
referred to as Churg-Strauss syndrome), and the so-
called renal-limited vasculitis [13]. From a clinical per-
spective it may be useful to think of GPA as having two
forms: a predominantly granulomatous form with mainly
localised disease with chronic course; and a florid, acute
small vessel vasculitic form characterised by severe pul-
monary haemorrhage and/or rapidly progressive vascu-
litis, or other severe vasculitic manifestation [13]. These
two broad presentations may co-exist or present sequen-
tially in individual paediatric and adult patients [13].
Therapeutic advances
Renal morbidity and mortality is a major concern in the
AAV, hence therapy aimed at preservation of renal func-
tion is a recurring theme for the treatment of AAV in
both adults and children [18]. Treatment for paediatric
AAV is broadly similar to the approach in adults based
on evidence derived from a number of clinical trials con-
ducted by the European Vasculitis Study group (EUVAS)
[19]. The EUVAS group was developed to conduct inter-
ventional clinical trials aimed at optimizing treatments
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clinical trials involving over 1300 patients have been
conducted that have defined the standard of care and
permitted consensus treatment recommendations [19].
Particular areas of focus were: the reduction in cyclo-
phosphamide exposure; efficacy of plasma exchange in
reducing renal morbidity; remission maintenance strat-
egies; and establishing the efficacy of newer therapies
[19]. Notably, two of the clinical trials have involved
children with AAV. These clinical trials, and how they
have informed current practice for both adults and chil-
dren with AAV are summarised below.
The CYCAZAREM trial (CYClophosphamide or AZA-
thioprine for REMission) recruited 144 new adult patients
with AAV and compared a 3–6-month cyclophosphamide
course, stopping when remission was achieved, to a stand-
ard 12-month course of cyclophosphamide. Both groups
were then switched to azathioprine as maintenance ther-
apy [20]. No differences in remission or relapse rates were
observed [20]. The validation of sequential cyclophospha-
mide induction followed by azathioprine maintenance has
subsequently served as the basis for later trials [20]. Pulsed
IV cyclophosphamide (CYCLOPS, CYCLophosphamide
Oral versus PulSed) was then shown to be as effective as
daily oral cyclophosphamide, with a 50 % reduction in cu-
mulative cyclophosphamide dose, and fewer adverse
events [21]. Based on these studies, current induction of
remission therapy in adults and children with AAV in-
cludes corticosteroids and cyclophosphamide (usually 6–
10 intravenous doses at 500–1000 mg/m2 [maximum
1.2 g] per dose, given every 3–4 weeks) [13, 19]. Intraven-
ous pulsed cyclophosphamide is increasingly favoured
over oral continuous cyclophosphamide in adults and
children, because the reduced cumulative dose, and less
neutropenic sepsis in adult patients, albeit without good
prospective paediatric evidence [13, 19].
In addition, B-cell depletion with rituximab has been ex-
plored as an alternative to cyclophosphamide for remis-
sion induction for AAV [22, 23]. Efficacy of this treatment
approach for severe renal disease in combination with two
IV cyclophosphamide doses was evaluated in the RITUX-
VAS trial [23]. This regimen had no benefit over a stand-
ard IV cyclophosphamide regimen in terms of efficacy or
adverse event rate; but demonstrated that rituximab could
provide clinically important cyclophosphamide sparing
[23]. Another US multicentre, randomized trial compared
rituximab with cyclophosphamide for remission induction,
and showed that rituximab was not inferior to daily oral
cyclophosphamide for induction of remission in severe
ANCA-associated vasculitis; and rituximab may be super-
ior in patients with relapsing disease [22]. These studies
led to licensing of rituximab for remission induction of
AAV in adults in the USA and Europe. Whether low-dose
cyclophosphamide still has a role in induction therapiesalongside rituximab remains uncertain. Notably, an on-
going international multicentre study is exploring the effi-
cacy and safety of Rituximab in children with new onset,
or relapsing AAV (the PEPRS study; NCT01750697).
Whilst we are encouraged that industry are supporting
and undertaking paediatric studies of new therapeutic
agents in rare diseases such as AAV, we appreciate that
studies of “older” drugs, or studies of combination drug
therapy in the paediatric population may not be feasible
(due to lack of industry support), even if desirable for
some diseases.
Two further EUVAS trials evaluated whether cyclo-
phosphamide could be replaced as an induction agent,
either with methotrexate or MMF. The NORAM trial
(Non-Renal Alternative treatment with Methotrexate)
demonstrated that remission rates for non-severe GPA/
MPA were similar at 6 months between an oral metho-
trexate and an oral cyclophosphamide regimen; but that
late relapse was more common after methotrexate [24].
MMF also proved not inferior to an IV cyclophospha-
mide regimen at 6 months in the MYCophenolate mofe-
til versus CYClophosphamide; MYCYC), trial but with a
higher relapse rate in the MMF group. The higher re-
lapse rate was confined to the PR3-ANCA-positive sub-
group, and no differences in remission or relapse rates
were seen in the MPO-ANCA patient subgroup [25].
Importantly, for the first time, children were included in
the MYCYC trial [25]. Many differences exist in physi-
ology, pathology, pharmacokinetics, and pharmaco-
dynamics between children and adults. Inclusion of
paediatric patients in large adult RCTs, therefore, by no
means eliminates the need for separate paediatric stud-
ies, but this approach at least allows us to obtain some
robust paediatric data rather than just directly extrapo-
lating from purely adult studies.
Regarding maintenance regimens, the EUVAS group
found MMF not to be superior to azathioprine for relapse
prevention of AAV after cyclophosphamide induction in
the IMPROVE trial [26]. MMF is therefore not recom-
mended as a routine remission maintenance agent, but can
be used when azathioprine or methotrexate have failed to
maintain remission in adults and children with AAV.
Rituximab was also considered to have role in relapse
prevention, and repeat-dose rituximab was shown to be
associated with fewer relapses than azathioprine, follow-
ing cyclophosphamide induction in the French MAIN-
RITSAN trial [27]. An ongoing study led by both
EUVAS and the Vasculitis Clinical Research Consortium
(VCRC) is exploring the role of rituximab in treatment
of relapsing disease in the RITAZAREM trial
(NCT01697267).
Other biologic agents that have been considered in
AAV therapy are anti-tumour necrosis alpha agents, but
these were largely abandoned after a negative result in
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cell co-stimulation inhibitor CTLA4-Ig (abatacept) is
currently being studied in a randomized trial for treat-
ment of non-severe, relapsing GPA (ABROGATE;
NCT02108860). The ALEVIATE trial (NCT01405807), a
small dose-finding trial of compassionate use of alemtu-
zumab (a monoclonal antibody against CD-52, found on
mature lymphocytes), is ongoing. For EGPA, a single-
centre, phase 2, uncontrolled study demonstrated that
mepolizumab (a monoclonal antibody against IL-5)
allowed glucocorticoid sparing over the course of the
disease in most patients, with no relapses during the ac-
tive 9-month treatment phase [29].
Lastly, the PEXIVAS trial is comparing four different
therapeutic combinations in a factorial design examining
a reduced oral glucocorticoid regimen with a standard-
dose regimen; with or without plasma exchange for
adults with AAV and renal involvement (NCT00987389).
Small case series have also indicated that plasma ex-
change reduces renal morbidity in children with AAV
[30]; but there are no ongoing or planned trials of thera-
peutic plasma exchange in children with AAV.
Kawasaki disease (KD)
Kawasaki disease (KD) is a self-limiting vasculitic syn-
drome that predominantly affects medium and small-
sized arteries [31]. KD has a worldwide distribution with
a male preponderance, an ethnic bias towards oriental
children, some seasonality, and occasional epidemics
[31]. The principal clinical features of Kawasaki disease
are: (i) Fever persisting for ≥5 days; (ii) Peripheral ex-
tremity changes (reddening of the palms and soles, in-
durative oedema and subsequent desquamation); (iii)
Polymorphous exanthema; (iv) bilateral conjunctival in-
jection/congestion; (v) lips and oral cavity changes (red-
dening/cracking of lips, strawberry tongue, oral and
pharyngeal injection); (vi) acute non-purulent cervical
lymphadenopathy [32]. For the diagnosis of Kawasaki
disease to be formally established five of the above six
clinical features should be present [32]. Children with
fewer than five of the six principal features can be diag-
nosed with Kawasaki disease when coronary aneurysm
or dilatation is recognized by two-dimensional echocar-
diography or coronary angiography [32].
Therapeutic advances
Early recognition and treatment of KD with aspirin and
intravenous immunoglobulin (IVIG) has been shown
unequivocally by randomised controlled trials and meta-
analysis to reduce the occurrence of CAA [32, 33]. Cur-
rently, aspirin at a dose of 30–50 mg/kg/day is recom-
mended during the acute phase of the illness, as this
may be better tolerated than higher doses in terms of
gastrointestinal and other side effects [31, 32, 34]. Thedose should be reduced to an anti-platelet does of 3–
5 mg/Kg once fever and inflammation have subsided
[31, 32, 34]. Notably however, IVIG resistance has been
reported in up to 20 % of cases and these patients are at
increased risk of developing CAA unless they receive
additional treatment [31]. Corticosteroids are effective
treatment for other forms of vasculitis, but early retro-
spective analyses suggested that corticosteroids were as-
sociated with increased risk of CAA [31]. However, this
almost certainly reflected selection bias as the sickest pa-
tients received steroids. Importantly, clinical trials evalu-
ating the use of corticosteroids plus IVIG have produced
seemingly confusing results, exemplified by a USA study
of high dose methyl prednisolone showing no reduction
in CAA, and the recent Japanese RAISE study (using a
lower dose but longer duration of prednisolone) showing
improved outcome [6, 35, 36]. Chen et al. recently re-
ported a meta-analysis comparing the frequency of CAA
in patients treated with IVIG plus corticosteroids or
IVIG alone for the primary treatment of KD [37]. They
found that significantly fewer patients receiving IVIG +
corticosteroids developed CAA than those receiving IVIG
alone (7.6 % versus 18.9 %; OR: 0.3; 95 % CI 0.20–0.46);
there was no significant differences in frequency of severe
adverse events between the steroid and non-steroid treat-
ment groups [37]. Chen’s meta-analysis provides convin-
cing evidence that steroids combined with IVIG as initial
treatment reduces overall risk of CAA in severe KD [37].
However, neither the meta-analysis nor the RAISE study
provides clear answers as to whether all children should
be treated with corticosteroids, and what dose, duration
and route of corticosteroids should be used [36, 37].
With these caveats in mind, we recently proposed a prag-
matic treatment approach for the use of corticosteroids
based on the current data and recognise that some children
would benefit from combination therapy of corticosteroid
and IVIG as first line therapy for KD (Fig. 1 [31].)
Furthermore, there are emerging animal data and
case reports suggesting a role for anti-TNF-α for the
treatment of KD [7, 38, 39]. The most commonly used
agent is infliximab, a chimeric murine/human IgG1
monoclonal antibody specifically binding TNF-α [7, 38,
39]. A recent multicentre study in the USA comparing
IVIG and aspirin to IVIG/aspirin plus infliximab as ini-
tial therapy in an unselected group of KD patients has
been completed and showed no reduction in CAA, al-
though there was faster resolution of the acute phase
response in the infliximab group [7]. Although there
was a trend towards reduced CAA injury, the study was
underpowered to detect significant reduction in CAA
[7]. Thus, anti-TNFα should be considered in patients
with IVIG resistant KD, but not routinely as adjunctive
and further study is required of its role in initial ther-
apy primary therapy.
Fig. 1 Recommended clinical guideline for the management of Kawasaki disease. Adapted from reference 31. *Treatment can be commenced
before 5 days of fever if sepsis excluded; treatment should also be given if the presentation is > 10 days from fever onset if there are signs of
persistent inflammation; **Kobayashi risk score ≥5 points X Refer to paediatric cardiologist; ¶ Other specific interventions such as PET scanning,
addition of calcium channel blocker therapy, and coronary angioplasty at discretion of paediatric cardiologist. + Other immunomodulators may
include ciclosporin. ♥For infants, Z score for internal coronary artery diameter >7 based on Montreal normative http://parameterz.blogspot.co.uk/
2010/11/montreal-coronary-artery-z-scores.html
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plored in KD. An open label study is currently examin-
ing the efficacy of anakinra as first line therapy in KD
(NCT02390596; KAWAKINRA). Another phase III mul-
ticentre, randomised, open-label, blinded-end point trial
is currently evaluating the efficacy and safety of im-
munoglobulin plus ciclosporin in patients with severe
KD in Japan (the KAICA Trial).
Polyarteritis nodosa (PAN)
Polyarteritis nodosa (PAN) is a primary systemic necro-
tizing vasculitis predominantly targeting medium-sized
arteries [1]. The classification criteria for childhood PAN
are histologic evidence of necrotizing vasculitis in
medium- or small-sized arteries or angiographicabnormalities (conventional angiography if magnetic res-
onance angiography is negative) as a mandatory criterion
plus one of the following five: skin involvement, myalgia
or muscle tenderness, hypertension, peripheral neur-
opathy, and renal involvement [4]. In children, various
systems are involved in PAN with the skin, the musculo-
skeletal system, the kidneys, and the gastrointestinal tract
most prominently affected; and cardiac, neurologic, and
respiratory manifestations occurring less frequently [1].
Therapeutic advances
Current treatment of PAN in children is based on lim-
ited trial data in adults. There are a number of RCTs for
treatment of PAN, all relating to adults [40–43]. Conclu-
sions based on RCTs in adults with PAN with important
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requires corticosteroids combined with intravenous
cyclophosphamide; b) despite therapy, mortality associ-
ated with PAN in adults remains high at 4–22 %; treat-
ment-related toxicity contributes to this; c) adverse
events (disease and treatment-related) affect 54–100 %
patients; and d) avoidance of cyclophosphamide in chil-
dren is desirable if alternatives exist since complications
associated with cyclophosphamide include infertility and
malignancy [40–43]. In line with this, in the largest pub-
lished cohort of paediatric PAN patients, cyclophospha-
mide was used in combination with steroids as first line
therapy in 83 % of the cases albeit with a number of sig-
nificant adverse events such as neutropenia and sepsis
noted [1]. Based on the fact that MMF appears to be an
alternative to cyclophosphamide for induction of remis-
sion in other systemic vasculitides and autoimmune dis-
eases with low toxicity profile, the MYPAN study
(Mycophenolate mofetil for childhood PAN) was set up
to explore whether MMF is non-inferior to cyclophos-
phamide, and with comparable (or less) short medium
term safety in children with PAN [25, 44]. Given that a
definitive trial analysed by frequentist statistical methods
would require 513 patients per arm and would take well
over 30 years to recruit [44], the MYPAN study adopts a
Bayesian approach, first characterising expert prior opin-
ion about the 6-month remission rate on CYC and the
relative benefit of MMF as probability distributions be-
fore the trial begins, and then updating these distribu-
tions using Bayes theorem once data become available
[44]. Using this rare disease trial design we hope to de-
liver the first clinical trial in childhood PAN.
Use of biologic agents, including anti TNF-α, and ri-
tuximab is also described for children with systemic
PAN, particularly those not responding to standard ther-
apy or because of concern regarding cumulative cyclo-
phosphamide toxicity [5]. These therapies have not been
formally assessed in RCTs in either children or adults
with PAN, however.
Takayasu arteritis
Takayasu arteritis (TA) is the only large vessel vasculitis
(LVV) referred to in the current paediatric classification,
affecting the aorta and its major branches [45]. TA has a
worldwide distribution, with a reported incidence of
1.2–2.6/million per year in Caucasians, and a 100-fold
higher incidence in East Asians [45, 46]. Although the
disease rarely affects children, it does occur even in in-
fants [2]. The clinical diagnosis of TA is usually challen-
ging [2, 47, 48]. An initial florid inflammatory vasculitic
phase is followed by a later fibrotic/stenotic phase of the
illness [2, 47, 48]. It is estimated that one-third of chil-
dren present within this late fibrotic/stenotic phase of
the disease [2, 47, 48]. It is a misconception that this isin some way an “inactive”, or “burnt-out” stage of the
disease, since progressive stenotic disease may be the
consequence of persistent but low-level large vessel vas-
culitic disease activity, but without evidence of conven-
tional laboratory markers of systemic inflammation such
as elevated C reactive protein, or increased erythrocyte
sedimentation rate [2, 47, 48]. Diagnostic delay in chil-
dren is unfortunately common and almost certainly con-
tributes to worse outcomes [2, 47, 48].
Although hypertension and/or its sequelae is the most
common form of presentation in both children and adults,
the overall clinical spectrum at presentation of children
with TA may differ from that in adults [2, 47, 48]. The
most frequent presentation in children is with arterial
hypertension (82 %) followed by headaches (31 %), fever
(29 %), dyspnoea (23 %), and weight loss (22 %) [2, 47, 48].
Musculoskeletal symptoms affect approximately 14–65 %
of children with TA [2, 47, 48]. In contrast, adults rarely
report arthritis or arthralgia. Bruits (48 %) and claudica-
tion (27 %) are more commonly reported in adults with
TA [2, 47, 48]. Ocular manifestations are also rare in chil-
dren [2, 47, 48]. A detailed overview of imaging in TA is
beyond the scope of this review, and we refer the reader
elsewhere for this [2].
Therapeutic advances in TA
There have been no randomised controlled trials to
guide treatment, and few evidence-based therapeutic ad-
vances. Biologic therapies are increasingly used in chil-
dren, particularly anti-TNFα [5], and anecdotally are
reported to be efficacious. A major therapeutic chal-
lenge, however, is that there remains significant diagnos-
tic delay for TA in children. This leads to significant and
sometimes irreversible damage in the pre-diagnostic
phase of the illness. At the time of writing, a major clin-
ical trial of tocilizumab (a monoclonal antibody against
the interleukin 6 receptor) for the treatment of giant cell
arteritis in adults is ongoing [49], and hopefully will re-
port later in 2016. It is debatable, however, what rele-
vance this might have for children with TA.
SHARE guidelines for the treatment of TA in the
paediatric population will be formally published soon.
The general therapeutic approach is that of induction of
remission (high dose corticosteroid combined with an-
other immunosuppressant), followed by maintenance of
remission therapy (lower dose corticosteroid combined
with a maintenance immunosuppressive agent, usually
methotrexate), or institution of second line therapy for
failed induction [2]. Corticosteroids are the mainstay of
first-line treatment for TA [2]. In addition, methotrexate,
azathioprine, MMF, and cyclophosphamide have been
used in children as first or second line agents [2, 47, 48].
Ozen, et al. described 6 children with TA, and treatment
with steroid and cyclophosphamide induction followed
Fig. 2 High power view of skin biopsy taken from an 8 week old
infant with CANDLE syndrome caused by digenic mutation in
PSMB4 and PSMB9. There is a florid leukocytoclastic cutaneous
vasculitis with karyorrhectic debris. In most areas distinct vessels
could not be identified due to the destructive vasculitic process
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TA [50]. Anti-TNF therapy may be beneficial [2, 51].
Promising results have also been reported with anti-IL6
therapy (tocilizumab) for adults with TA, and in some
cases children [52, 53]. Surgical intervention is frequently
required to alleviate end-organ ischemia and hypertension
resulting from vascular stenosis, although it is preferable
to control the vasculitic process before performing revas-
cularisation procedures or other vascular surgery, if pos-
sible, since outcomes are worse if these are undertaken
when the disease is still active [2, 47, 48].
The 5 year mortality rate of TA in children has been
reported as high as 35 %; we recently reported 27 %
mortality from TA in children [2]. Prognosis is
dependent upon the extent of arterial involvement and
organ damage at presentation; age of patient at disease
onset (children under 5 have poorer prognosis); and on
the severity of hypertension [2, 47, 48]. It is unlikely that
a randomised controlled trial for TA in children will be
undertaken in the foreseeable future; extrapolation from
adult trials (such as the soon-to-be reported tocilizumab
trial) will provide some evidence base, but with all the
caveats around using data from adult trials to inform
paediatric practice.
Monogenic vasculitides: DADA2; CANDLE; and
SAVI
Three recently described monogenic autoinflammatory
conditions with a major vasculitic component are
worthy of description in brief, since they highlight the
concept that understanding the molecular pathogenesis
may lead to more targeted therapy [54–57].
DADA2
Deficiency of adenosine deaminase type 2 (DADA2) is an
autosomal recessive disease resembling polyarteritis
nodosa, caused by homozygous or compound heterozy-
gous mutations in the CECR1 gene [54, 55]. The cardinal
clinical features include livedo racemosa, neurological in-
volvement including propensity to lacunar (small vessel)
stroke, vasculitic peripheral neuropathy, digital ischaemia
and cutaneous ulceration, systemic inflammation, and
other end organ damage [54, 55, 58, 59]. There is an emer-
ging view that anti TNF alpha is particularly efficacious
for this form of monogenic vasculitis [59]; this may be due
to the fact that the extracellular enzyme ADA2 functions
as an important regulator of immune development. Pa-
tients with DADA2 demonstrate skewed macrophage de-
velopment towards the M1 pro-inflammatory phenotype
as opposed to the M2 anti-inflammatory phenotype [54,
55]. M1 macrophages are known to produce TNF alpha,
which could explain why this therapeutic approach seems
particularly effective in DADA2 [54, 55]. Allogeneic haem-
atopoietic stem cell transplantation has been reported tobe successful in a few patients [60]; gene therapy may be
an option for the future [59].
CANDLE and SAVI
CANDLE syndrome (Chronic Atypical Neutrophilic
Dermatosis with Lipodystrophy and Elevated temperature)
is a recessive disease caused by homozygous, compound
heterozygous or digenic mutations in the proteasome
pathway, and is classified as a proteasome-associated auto-
inflammatory syndrome (PRAAS) [57, 61]. Mutations in
PSMB8, PSMB4, PSMB9, PSMA3, and proteasome matur-
ation protein (POMP) are described [57, 61]. In the early
stages, the neutrophilic dermatosis may display the histo-
logical features of neutrophilic/leukocytoclastic vasculitis
(Fig. 2). CANDLE is associated with dysregulated type I
interferon production, therefore targeting this pathway
with Janus kinase (JAK) inhibitors may be a promising
novel therapeutic approach [57, 61]. Early clinical trials of
baricitinib, an oral JAK1 and JAK2 inhibitor, are ongoing.
Stimulator of interferon genes (STING)-associated
vasculitis of infancy (SAVI) arises from sporadic/domin-
ant mutation in the TMEM173 gene and presents early
in life with a vasculitic rash affecting the cheeks, nose,
and peripheries (Fig. 3) with chronic ulceration; and pro-
gressive interstitial pulmonary fibrosis and associated
pulmonary hypertension [56, 62]. Standard vasculitis
therapies are ineffective. Cutaneous vasculitis and deteri-
orating lung function usually continue relentlessly
throughout childhood, with development of pulmonary
hypertension and lung fibrosis, often with fatal outcome
[56, 62]. SAVI is considered part of the growing group of
Mendelian disorders recognised as “interferonopathies”
which include Aicardi–Goutières syndrome (AGS), and
Fig. 3 Chronic scarring of the pinna in a 12-year old boy with SAVI
Eleftheriou and Brogan Pediatric Rheumatology  (2016) 14:26 Page 8 of 9the aforementioned CANDLE syndrome [63]. Whilst
there are virtually no published data currently available,
anecdotal reports again suggest that early treatment tar-
geting the interferon pathway (e.g. with JAK inhibitors)
currently offers the best hope for survival.Concluding remarks
Considerable therapeutic advances for the treatment of
vasculitis of the young have been made in the past
10 years, including the development of outcome mea-
sures that facilitate clinical trial design. Notably, these
include: a recognition that some patients with KD re-
quire corticosteroids as primary treatment combined
with IVIG; implementation of rare disease trial design
for PAN to deliver the first randomised controlled trial
for children; first clinical trials involving children for
ANCA vasculitis (MYCYC and PEPRS); and identifica-
tion of monogenic forms of vasculitis that provide an
understanding of pathogenesis facilitating more targeted
treatment [31, 44, 54–57]. Priorities for future research
have been identified including a need for robust rando-
mised controlled trials for HSPN; therapeutic trials for
TA; and an over-arching need for trials examining new
agents that facilitate corticosteroid sparing, of particular
importance in the paediatric population since gluco-
corticoid toxicity is a major concern.Competing interests
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